Nwe Saw Yu, Chitapanarux Imjai, Nobnop Wannapha
Graduate School, Medical Physics Program, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Division of Radiation Oncology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Northern Thai Research Group of Radiation Oncology (NTRG-RO), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Med Dosim. 2023;48(1):16-19. doi: 10.1016/j.meddos.2022.09.002. Epub 2022 Oct 25.
The objective of the study is to verify the dose delivered on helical tomotherapy based on treatment plan with varying virtual bolus (VB) thickness. The target was localized on the ArcCHECK image by 3 mm margin from the phantom surface. The dimension of target, which includes the ArcCHECK's detectors, with the 4.0 cm width and length 12.0 cm along the phantom The 5 treatment plans were generated, 1 plan without VB application (NoVB) and the 4 plans with varying of VB thickness on the phantom surface by 0.5 cm (VB0.5), 1.0 cm (VB1.0), 1.5 cm (VB1.5), and 2.0 cm (VB2.0), in treatment planning but absent during irradiation. For measurement analysis, the ionization chamber and the ArcCHECK detectors were used for point dose and dose distribution by investigating the percentage of dose difference and the gamma passing rate. The VB thickness 0.5, 1.0 and 1.5 cm showed acceptable value with less than 2% for dose difference by 0.37% (VB0.5), -0.11% (VB1.0) and -0.37% (VB1.5) at the center of ArcCHECK. The accuracy of dose distribution showed an acceptable gamma passing rate of 99.8% (VB0.5), 100% (VB1.0), and 90.2% (VB1.5) for gamma criteria by 3%/3mm for absolute dose analysis. However, the gamma passing rate of VB2.0 down to 71.2% of absolute mode for gamma criteria by 3%/3mm. The treatment plans with VB thickness less than 15 mm deliver doses that are comparable to treatment plans without virtual bolus based on gamma analysis. However, the deviation showed a trend increasing when VB thickness increased. The VB2.0 was not acceptable for point dose and dose distribution verification by more than 2% dose difference and less than 90% of gamma passing rate.
本研究的目的是基于具有不同虚拟 bolus(VB)厚度的治疗计划,验证螺旋断层放疗所输送的剂量。通过在 ArcCHECK 图像上从体模表面向外 3 毫米的边界来定位靶区。靶区的尺寸包括 ArcCHECK 的探测器,其宽度为 4.0 厘米,沿体模长度为 12.0 厘米。生成了 5 个治疗计划,1 个不应用 VB(NoVB)的计划,以及 4 个在治疗计划中体模表面 VB 厚度分别变化为 0.5 厘米(VB0.5)、1.0 厘米(VB1.0)、1.5 厘米(VB1.5)和 2.0 厘米(VB2.0)但在照射期间不存在的计划。为了进行测量分析,通过研究剂量差异百分比和伽马通过率,使用电离室和 ArcCHECK 探测器来测量点剂量和剂量分布。VB 厚度为 0.5 厘米、1.0 厘米和 1.5 厘米时显示出可接受的值,在 ArcCHECK 中心的剂量差异小于 2%,分别为 0.37%(VB0.5)、-0.11%(VB1.0)和 -0.37%(VB1.5)。对于绝对剂量分析,伽马标准为 3%/3 毫米时,剂量分布的准确性显示出可接受的伽马通过率,VB0.5 为 99.8%,VB1.0 为 100%,VB1.5 为 90.2%。然而,对于伽马标准为 3%/3 毫米的绝对模式,VB2.0 的伽马通过率降至 71.2%。基于伽马分析,VB 厚度小于 15 毫米的治疗计划所输送的剂量与无虚拟 bolus 的治疗计划相当。然而,当 VB 厚度增加时,偏差呈增加趋势。VB2.0 在点剂量和剂量分布验证方面不可接受,剂量差异超过 2%,伽马通过率低于 90%。